TCTR20170929003尚未招募3 期
A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (STELLA)
mAbxience S.A0 个研究点目标入组 650 人开始时间: 2017年9月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •- Males and female subjects aged 18Â years or above to less than or equal to 80 years
- •- Signed informed consent must be obtained before initiation of any study-specific procedures or treatment as confirmation of the subject’s awareness and willingness to comply with the study requirements.
- •- Subjects should have newly diagnosed or recurrent Stage IIIB/IV nonsquamous NSCLC (defined by seventh edition of the TNM classification for Lung Cancer, 2010) not amenable to curative intent surgery, and not have received any systemic therapy for advanced disease. For subjects with recurrent disease, at least 6 months must have elapsed from previous adjuvant treatment.
排除标准
- •Inability to comply with protocol procedures
研究者
相似试验
已完成
不适用
Compare the effects of Avastin and Avastin combined with methylcellulose in intraocular pressure after Non-penetrating glaucoma surgeryglaucoma.Primary open-angle glaucoma Glaucoma (primary)(residual stage): capsular with pseudoexfoliation of lens chronic simple low-tension pigmentaryIRCT2016121831450N1Vice Chancellor for research of Tabriz University of Medical Sciences30
已完成
2 期
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent GlioblastomaGlioblastoma MultiformeNCT01474239Hoffmann-La Roche91
进行中（未招募）
不适用
Randomised phase II trial of bevacizumab (AVASTIN) in combination with gemcitabine or attenuated doses of cisplatin and gemcitabine as first-line treatment of elderly patients with advanced, metastatic non-squamous non-small cell lung cancer. - EAGLESEUCTR2008-008739-27-ITROCHE78
进行中（未招募）
不适用
A RANDOMIZED PHASE II STUDY COMPARING IMATINIB AND THE COMBINATION OF IMATINIB AND PEGYLATED INTERFERON ALPHA-2B IN NEWLY DIAGNOSED NON-HIGH RISK CHRONIC MYELOID LEUKEMIA PATIENTS IN COMPLETE HEMATOLOGICAL REMISSION AFTER IMATINIB INDUCTION THERAPY - Nordic IR-LR Studyewly diagnosed chronic myeloid leukemia (CML) belonging to intermedia (IR) or low risk (LR) by the Sokal prognostic scoreEUCTR2004-002504-15-FIThe Nordic CML Study Group120
已完成
2 期
A Phase II Study of Bevacizumab (Avastin®) in Combination with Standard Second line chemotherapy (Docetaxel Or Pemetrexed) in Patients with Non-Squamous Non-Small-Cell Lung Cancer previously Treated with chemotherapyon-sq NSCLC with previously treatedJPRN-UMIN000007123Hiroshima University Hospital Respiratory medicine34